Short Term Effect of Empagliflozin in Hypertension

Short Term Effect of Empagliflozin on Left Ventricular Relaxation in Non Diabetic Hypertensive Patients

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04203914

Acronym

EMPHYT

Enrollment

Registered

2019-12-18

Start date

2017-01-10

Completion date

2017-09-30

Last updated

2019-12-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Keywords

Hypertension, Empagliflozin, Left ventricular diastolic function, Blood pressure

Brief summary

The investigators assessed the 6-week effect of once daily 25mg SGLT2-i Empagliflozin on left ventricular diastolic function and blood pressure profile in non diabetic hypertensive patients

Detailed description

Background: The rapid beneficial effects of Empagliflozin on cardiovascular mortality and hospitalizations rates for heart failure according to the Cardiovascular Outcome Event Trial in Type 2 Diabetes Mellitus Patients (EMPA-REG OUTCOME) trial raise some question in the mechanism of myocardial action. The investigators conducted this study in a population of non-diabetic hypertensive patients in order to look for a short-term effect on left ventricular relaxation. Methods: The investigators carried out a single arm non- randomized clinical trial and assigned patients to receive 25mg of empagliflozin once daily in additional therapy for six weeks at the National Center for Obesity and in the cardiology department of Yaounde Central Hospital in hypertensive patients with cardiac relaxation disorder. The objectives were to evaluate the left ventricular diastolic function and nycthemeral blood pressure profile.

Interventions

DRUGEmpagliflozin Tablets

Add-on 25mg once daily

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Intervention model description

Open label trial with before and after design

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* Grade 1 hypertension * Grade 1 or 2 relaxation abnormalities (Doppler E/A ratio \<1) * Unchanged antihypertensive treatment for at least 12 weeks

Exclusion criteria

* Diabetes mellitus * eGFR \< 60 mL/min/1,73 m² * Mitral stenosis * Atrial fibrillation * Alanine transferase above 2N

Design outcomes

Primary

Measure	Time frame	Description
Left ventricular diastolic function	6 weeks	Doppler ultrasound measured relaxation

Secondary

Measure	Time frame	Description
Blood pressure	6 weeks	24-h ambulatory blood pressure
HbA1c	6 weeks	Glycated haemoglobin

Countries

Cameroon

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 19, 2026